Cited by 315Hereditary Neurological DisordersGenetic Neurodegenerative DiseasesNeurogenetic and Muscular Disorders Research

Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients

Schüle, Rebecca, Wiethoff, Sarah, Martus, Peter, Karle, Kathrin N., Otto, Susanne, Klebe, Stephan, Klimpe, Sven, Gallenmüller, Constanze +14 more·2016·Annals of Neurology

Abstract

Objective: Hereditary spastic paraplegias (HSPs) are genetically driven disorders with the hallmark of progressive spastic gait disturbance. To investigate the phenotypic spectrum, prognostic factors, and genotype‐specific differences, we analyzed baseline data from a continuous, prospective cohort. Methods: We recruited 608 HSP cases from 519 families of mostly German origin. Clinical severity was assessed by the Spastic Paraplegia Rating Scale. Complicating symptoms were recorded by a standardized inventory. Results: Family history indicated dominant (43%), recessive (10%), and simplex (47%) disease. We observed a significant male predominance, particularly in simplex cases without a genetic diagnosis. Disease severity increased with disease duration. Earlier disease onset was associated with less severe disease. Specific complicating features including cognitive impairment, extrapyramidal or peripheral motor involvement, and ataxia were associated with worse disease severity. Disease severity also depended on the genotype. HSP cases maintained the ability to walk independently for a median disease duration of 22 years. Early onset cases were able to maintain free walking significantly longer and were at less risk to become wheelchair dependent. Interpretation: This cross‐sectional cohort study provides the first large‐scale data on disease manifestation, progression, and modifying factors, with relevance for counseling of HSP families and planning of future cross‐sectional and natural history studies. Later age of onset, specific complicating features, and the SPG11 genotype are strongly associated with more severe disease. Future interventional studies will require stratification for modifiers of disease progression identified in this study. Prospective longitudinal studies will verify progression rates calculated in this baseline analysis. Ann Neurol 2016;79:646–658

Integrity signals

Registry

Crossref · 10.1002/ana.24611

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schüle, R., Wiethoff, S., Martus, P., Karle, K. N., Otto, S., Klebe, S., Klimpe, S., Gallenmüller, C., Kurzwelly, D., Henkel, D., Rimmele, F., Stolze, H., Kohl, Z., Kassubek, J., Klockgether, T., Vielhaber, S., Kamm, C., Klopstock, T., Bauer, P., Züchner, S., Liepelt‐Scarfone, I., & Schöls, L.
Affiliations
  • University of Miami (US)
  • Hertie Institute for Clinical Brain Research (DE)
  • University of Tübingen (DE)
  • German Center for Neurodegenerative Diseases (DE)
  • St. Josef-Hospital (DE)
  • University Medical Center Freiburg (DE)
  • Johannes Gutenberg University Mainz (DE)
  • University Hospital Bonn (DE)
  • DIAKO (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Universität Ulm (DE)
  • Dr John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics University of Miami Miller School of Medicine Miami FL
Corresponding author
Schöls, Ludger
Venue
Annals of Neurology
Publisher
Wiley
Published
2016-03-11
Volume
79
Issue
4
Pages
646-658
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2266150566
Cited by
315
References
1
Citations by year
2026: 26 · 2025: 23 · 2024: 46 · 2023: 27 · 2022: 58 · 2021: 36 · 2020: 23 · 2019: 35 · 2018: 16 · 2017: 11 · 2016: 12
FWCI
13.84
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • DZNE Pub (submittedVersion)
Funders
  • German Ministry of Education and Research (01GM0603)
  • German Ministry for Education and Research (01GM0807)
  • European Union within the 7th European Community Framework Program (F5-2012-305121)
  • E-Rare Network NEUROLIPID (01GM1408B)
  • Marie Curie International (PIOF-GA-2012-326681)
  • Center for Clinical Research Tübingen (1970-0-0)
  • German HSP-Selbsthilfegruppe
  • DZNE intersite project
  • Spastic Paraplegia Foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Health Sciences › Medicine › Genetics › Neurogenetic and Muscular Disorders Research
Keywords
hereditary spastic paraplegia, disease severity, disease progression, age of onset, SPG11, cognitive impairment, ataxia, wheelchair dependence, natural history (disease), family history (medicine), genotype-phenotype correlation
MeSH terms
Adult, Aged, Cross-Sectional Studies, Female, Germany, Humans, Male, Middle Aged, Pedigree, Severity of Illness Index, Spastic Paraplegia, Hereditary

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review